Page Loading...
Layout Table~~~~2484~2484~~
In Vitro Diagnostics Market Report & Analysis 2008-2023~
Published by VisionGain, June 2008

This brand new report examines the commercial prospects for in vitro diagnostics (IVD) in the global healthcare market. Technological solutions are playing an increasingly important role in both clinical practice and pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, current developments in diagnostics – especially molecular diagnostics - are paving the way towards the long-held goal of personalised medicine, to the benefit of patients, companies and healthcare providers. Developments in IVD also receive encouraging support from regulators such as the FDA. Visiongain believes that some of the greatest opportunities ever available for diagnostics companies are now there to be seized, with important sales, licensing and partnership developments from the present onwards.~Published by VisionGain, June 2008

This brand new report examines the commercial prospects for in vitro diagnostics (IVD) in the global healthcare market. Technological solutions are playing an increasingly important role in both clinical practice and pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, current developments in diagnostics – especially molecular diagnostics - are paving the way towards the long-held goal of personalised medicine, to the benefit of patients, companies and healthcare providers. Developments in IVD also receive encouraging support from regulators such as the FDA. Visiongain believes that some of the greatest opportunities ever available for diagnostics companies are now there to be seized, with important sales, licensing and partnership developments from the present onwards.

Importantly, this report also covers theranostics, a fusion of drug therapy and diagnostics to optimise efficacy and safety, as well as streamlining drug development. Combining a drug with a diagnostic process or test is also known as companion diagnostics, integrated medicine, pharmacodiagnostics and Dx/Rx partnering. This emerging field is generating strong interest from the healthcare industry and regulatory bodies, with the associated market expanding as the importance of theranostics is recognised, especially in cancer.

Our new In Vitro Diagnostics Market Report & Analysis 2008-2023 report examines the market for in vitro diagnostic solutions critically, through comprehensive primary and secondary research. Importantly, visiongain discusses IVD in the context of the wider healthcare market, with a strong emphasis on theranostics and related molecular diagnostics/medicine. In addition to consultation with experts in industry - including full interview transcripts - this research involved a detailed study of relevant documents, industrial reports and current developments. Vitally, visiongain applied unique in-house forecasting techniques and analysis of drivers and restraints. The result is a totally independent in-depth market-based report with detailed analyses and informed opinion.

In particular, this report concentrates on the following essential aspects of the in vitro diagnostics sector:Why you should buy this report: Visiongain predicts that the markets for IVD and theranostics will exhibit strong growth in revenues from 2008-2023, with significant investments being made by far-sighted companies and healthcare providers. Although still in its early stages of commercial development, molecular diagnostics will increasingly gain acceptance from stakeholders in healthcare. You should be benefiting from this opportunity. You and your company can benefit as a result, gaining early market prominence from high-value products. You cannot afford to ignore current developments in diagnostics, especially as personalised medicine becomes an inevitable reality.

Sample Pages~~2484~3357~~
Emerging Markets for Microfluidic Applications~
Published by Yole Développement, May 2007

Microfluidics is becoming a key technology integrated in most of Life Science companies’ development roadmap. Drug discovery remains today the first microfluidics market. Microfluidics key advantage is to enable higher analysis throughput while decreasing analysis time and cost. Firstly used at the system level for liquid handling, microfluidics technology is also successfully integrated in cartridges for research applications. Commercialised by SME and big instrumentation companies, microfluidics products are bound to be part of the gold standard technologies used in research applications.~Published by Yole Développement, May 2007

Drug discovery remains today the first microfluidics market. Microfluidics key advantage is to enable higher analysis throughput while decreasing analysis time and cost. Firstly used at the system level for liquid handling, microfluidics technology is also successfully integrated in cartridges for research applications. Commercialised by SME and big instrumentation companies, microfluidics products are bound to be part of the gold standard technologies used in research applications.

The microfluidics market for research applications will steadily grow in the 5 coming years, but the double digit growth will come from the diagnostic market. Indeed microfluidics has a strong competitive advantage in this market enabling analysis automation and decentralisation, but also in facilitating the molecular diagnostic emergence and success.

Microfluidics components for diagnostic are expected to reach €1b market value in 2011 with a Total Accessible Market of about 5b€.

If microfluidics proof of concept is validated now, no real standard has been defined yet. Dedicated to research applications, microfluidics products are rather produced in low volume. The microfluidics penetration in the diagnostic market will require the technology validation from a manufacturability point of view. Only the technologies fitting with the diagnostic market cost and regulation pressure will success.

Such standardisation will lead to a structuration of the industrial food chain. New players are entering the field. Some microfluidics companies adapt their business model to the market evolution. Mergers and acquisitions are also increasing.

Most of diagnostic companies have positioned microfluidics in their development roadmap as a key technology to support their growth strategy.

Indeed microfluidics is clearly identified as an enabling technology to support the development of the point of care and the molecular biology markets.

All ingredients are gathered for success:

1 - Microfluidics is overcoming the proof of concept milestones. Some companies are today positioned in microfluidics industrialisation

2 - Microfluidics provides the expected technical solutions required in the diagnostic market evolution

3 - Innovative high tech companies are entering the diagnostic field. They will participate to the market dynamism in facilitating convergence of technologies like microfluidics and biomarkers.~Emerging Markets for Microfluidic Applications (Single User License)|1052|Emerging Markets for Microfluidic Applications (Corporate License)|1182|Emerging Markets for Microfluidic Applications (Corporate Multi Site License)|1183|~2484~3202~~
LifescienceIC~
Published by Yole Développement, April 2006

The purpose of the report is to provide a better understanding of Life Sciences to semi-conductor and MEMS companies, with a detailed analysis of the different application fields, market evaluation and strategy analysis for semiconductor and MEMS companies. This report presents and describes the biological challenges ins and out. It highlights the specificities of the different Life Science industries and the business opportunities for semiconductor and MEMS companies. It also answers the question: “how could IC and MEMS companies become a key leader of the Life Sciences field?”~Published by Yole Développement, April 2006

A very futuristic approach of Life Sciences is on the way. New in vitro diagnostics systems, new therapy strategies, genetic diseases treatment, targeted and intelligent drug delivery, artificial pancreas… are health improvement promised to the future generations, enabled by semiconductor and MEMS technologies. The Life Sciences industry is already facing very important challenges to take its way to this expected innovation breakthrough.

Such future of Life Sciences will be possible by bringing together many different technologies like microelectronics, mechanics, optics, physics, molecular biology… Indeed microelectronics that has led to the explosion of consumer electronics sales could now bring its added value to different to the Life Science applications. The key challenge for microelectronics is to make complexity invisible, to make technology accurate, reproducible and intuitive for a natural use. They are already used for drug delivery dedicated products.

This expected evolution in the Life Sciences field requires thus teams from different background to collaborate and to understand the challenges each other is facing in its own domain. It involves being able to understand the biological ins and out as well as challenges to work together in identifying an innovative solution to propose.

To take part in this innovation process, it is very important to understand the technology and industrial trends by having a good view on the current technologies used, their limits and advantages, the applications and the way Life Science is working.

The Life Sciences field is considered as a very attractive field to target for the next innovation to launch. Some companies already succeed as shows the Affymetrix success story. In a little more than 10 years, using its technology coming from the semiconductor field and with key agreements with Life Science companies (Roche, Novartis, Aventis, BMS, bioMérieux…), Affymetrix is now dominating the biochip market worldwide with more than 70% market shares.

Several semiconductor companies are involved in Life Sciences like STMicroelectronics, Philips, Agilent… and several others have stopped their activity like Motorola, Infineon… Entering the Life Sciences field could be complex since it is a very broad field including many different industries like drug discovery, in vitro diagnostic, medical devices, instrumentation…

The market is much segmented in term of applications, technologies and medical use. Each field has its own specificity in term of industry organization, added value chain, industrial players, R&D activities, drivers and market entry barriers, entry point in the supply chain, position in the value chain… For example, selling devices is not always the best way to maximise the added value compared to a module/function approach. One of the main challenges in entering the Life Sciences field is to define the value of the technology to propose in this business.

The purpose of the report is to provide a better understanding of Life Sciences to semi-conductor and MEMS companies, with a detailed analysis of the different application fields, market evaluation and strategy analysis for semiconductor and MEMS companies.

This report presents and describes the biological challenges ins and out. It highlights the specificities of the different Life Science industries and the business opportunities for semiconductor and MEMS companies. It also answers the question: “how could IC and MEMS companies become a key leader of the Life Sciences field?”

LifescienceIC report will introduce you to molecular biology with basic concepts presentation so that you get a better understanding of the biology field and challenges. We particularly describe biological compounds (nucleic acids, proteins, peptides, glycanes etc...), their size scales and interaction to highlight and make understandable the biological complexity.

A part of this report is also dedicated to the different existing techniques used today in molecular biology. We highlight the gold standard technologies per application field. Such information is required to get a technological and commercial competitive advantage. Sample preparation, PCR amplification, nucleic acids and proteins separation and detection, immunoassays, HPLC columns and mass spectrometry are examples of technologies described.

The industrial fields where semiconductor technology could be used will be presented, highlighting the market potential ($), players involved, and key specificities. The report also defines the attractive functions from semiconductor devices. It is illustrated by current products and developments.~LifescienceIC (Single User License)|1048|LifescienceIC (Corporate License)|1184|LifescienceIC (Corporate Multi Site License)|1185|~2484~3192~~
Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D~
Companies Products and WW Market, 2004-2009

Published by Takeda Pacific, July 2005

One of the big ideas that emerged since the completion of the human genome project involves new biomarkers and tests used for tailoring new drugs that match an individual’s genetic makeup. This report is about the market for genomic, metabolomic and protein biomarkers and the related tests. The tests are used as molecular diagnostics and as pharmacogenomic assays to measure drug safety or effectiveness. Takeda Pacific’s report maps out the major areas of the market ecosystem for biomarkers and related tests. This insightful study shows that this market is big business and reached $7.1 billion in 2004. The study reveals that molecular diagnostic companies are poised for continued strong growth. The mix of pharma/ biotech companies doing biomarker related R&D is also beginning to show gains.

~Companies Products and WW Market, 2004-2009

Published by: Takeda Pacific, July 2005


One of the big ideas that emerged since the completion of the human genome project involves new biomarkers and tests used for tailoring new drugs that match an individual’s genetic makeup. This report is about the market for genomic, metabolomic and protein biomarkers and the related tests. The tests are used as molecular diagnostics and as pharmacogenomic assays to measure drug safety or effectiveness. Takeda Pacific’s report maps out the major areas of the market ecosystem for biomarkers and related tests. This insightful study shows that this market is big business and reached $7.1 billion in 2004. The study reveals that molecular diagnostic companies are poised for continued strong growth. The mix of pharma/ biotech companies doing biomarker related R&D is also beginning to show gains.

The study projects the 5-year trends for biomarkers, molecular diagnostics and pharmacogenomic tests used by the drug makers. The report charts the developments of more than 50 companies involved in this dynamic industry.

This report discusses new FDA initiatives to accelerate the approvals of emerging diagnostics and new drugs by integrating biomarkers and pharmacogenomic tests drug development from pre-clinical through the end of clinical trial phases. Companies have responded with new products. Roche’s new microarray test, targets certain gene variants, and tests if patients respond well to 30 or more currently marketed drugs. Tailored therapies such as Herceptin, Gleevec, Erbitux, or Irressa are among a new class of marketed products. They work very effectively, but just for a sub-set of individuals that pass special genetic tests designed for each product. These products signal that the era of personalized medicine has begun.

This study is packed with interesting data and includes more than 66 figures and tables. The tables provide data about technologies, companies, product pipelines, partnerships and more. The study also has additional data such as the worldwide incidence and prevalence of major diseases. The report analyzes partnering deals and includes several years of alliance and M&A data.

Twenty-two selected companies are profiled, with details including contact information, business and product overviews, alliances and patent or other financial details. This report would benefit people with job titles including CEO, VPs, Director of Business Development, Research Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research Scientists, Consultants or Industry Analysts.

Table of Contents~Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D%3A PDF Single User License|52|Biomarkers and Related Tests for Molecular Diagnostics and Pharma/ Biotech R&D%3A Site License|53|~2484~2685~~

Medical Biosensor Applications and Market to 2008~
Diabetes Management, Point-of-Care and Related Applications

Published by Takeda Pacific, May 2005

This insightful report discusses the global market for medical biosensors and offers readers interesting information and analysis about key developments driving this market. The study details how medical biosensors are utilized in key medical applications. These applications include home blood glucose monitoring used for diabetes management and clinical biosensor applications including Point-of-Care-Testing devices, IV diagnostics and related applications.~Diabetes Management, Point-of-Care and Related Applications

Published by Takeda Pacific, May 2005

This insightful report discusses the global market for medical biosensors and offers readers interesting information and analysis about key developments driving this market. The study details how medical biosensors are utilized in key medical applications. These applications include home blood glucose monitoring used for diabetes management and clinical biosensor applications including Point-of-Care-Testing devices, IV diagnostics and related applications.

The surge in obesity and the disturbing growth rate of diabetes in the developed world is driving a need for better diabetes management products. Glucose monitors will continue to play an important role in this field. In hospitals, there is a continual need for medical biosensor based devices that are used for real-time Point-of-Care Testing or monitoring of blood gases, other vital signs, and related clinical applications. The acute shortage of available livers, pancreatic cells and kidneys for transplant is driving the need for life sustaining artificial organs. Innovative medical biosensor devices are being developed to work as part of artificial organs such as artificial pancreas, liver or kidney.

Many organizations are working in this field and are seeking new business opportunities. This report discusses the major areas of commercial and R&D activities at academic, private or public centers. This study estimates that the market size for global medical biosensor-based products in 2004 reached about $7.1 billion and is growing at about 9.7% to 2008. Company profiles and tables provide insights about products and trends. The study uses 25 figures and tables to provide the reader with key information

This report would benefit people with job titles including CEO, VPs, Director of Business Development, Research Directors, Entrepreneurs, Venture Capitalists, Investment Planners, Research Scientists, Consultants or Industry Analysts.

Table of Contents~Medical Biosensor Applications and Market to 2008%3A PDF Single User License|68|Medical Biosensor Applications and Market to 2008%3A Site License|69|~2484~2485~~
Molecular Diagnostics~
Published by Select Biosciences, Spring 2005

The molecular diagnostics marketplace offers a growth opportunity given the interest in utilizing molecular tools to precisely target therapeutics.

This report analyzes the technologies and their impact in the molecular diagnostics marketplace. An assessment of all the technologies of value in this market and which market segments are impacted and affected by these technologies.

Furthermore, in this report are presented qualitative and quantitative market analysis of molecular diagnostics. Presented are total industry revenues, growth rates, and the various qualitative drivers that are contributing to the growth of the marketplace.
~Untitled DocumentPublished by Select Biosciences, Spring 2005

The molecular diagnostics marketplace offers a growth opportunity given the interest in utilizing molecular tools to precisely target therapeutics.

This report analyzes the technologies and their impact in the molecular diagnostics marketplace. An assessment of all the technologies of value in this market and which market segments are impacted and affected by these technologies.

Furthermore, in this report are presented qualitative and quantitative market analysis of molecular diagnostics. Presented are total industry revenues, growth rates, and the various qualitative drivers that are contributing to the growth of the marketplace.

Key Highlights of this Report:

• Qualitative and quantitative market analyses, and market forecasts
• Technology assessment and competitive analysis
• All the major technology platforms deployed in molecular diagnostics:
    o Instrumentation
    o Complete Assay Technologies
• Approval processes for molecular diagnostics for US, European Union, and Japan are presented. This is key information for new entrants into this marketplace.
• Segments of the molecular diagnostics marketplace
• Qualitative market drivers
• Quantitative Market Analysis
    o Total market size in terms of industry revenues and growth rate
    o Emerging market segments-and estimated market sizes
    o Growth areas in terms of classes of analytes-biological targets for development of molecular diagnostics

Companies mentioned in the report

A&G Pharmaceutical
Abbott Laboratories
Affymetrix
Amorfix Life Sciences
AstraZeneca
Axis-Shield
Bayer
Biogen Idec
Bristol-Myers Squibb
Cambridge Theranostics
Chiron
Clinical Data
CyGene
DakoCytomation
Digene
DNAPrint Genomics
Epigenomics
EXACT Sciences
Fornix Theranostics
Gemini (Eurona)
Genaissance Pharmaceuticals
Genentech
Genetic Vectors
Gen-Probe
Glaxo Wellcome
HBV Theranostica
Hyseq
IGEN International
ImClone Systems
Innogenetics
Investigen
Itsi-Biosciences
Kingo Diagnostika
Lpath Therapeutics
Merck & CO.
Millennium Predictive Medicine
Myriad Genetics
Neighborhood Connections
NGI
Novartis
Oncogene Science
Organon Teknika
PeptiFarma
PGxHealth
PharmaNetics
Pronto Diagnostics
Provalis
Quidel
Roche
Seapro Theranostics International B.V
Sequenom
The Boston Consulting Group
TheraNostics GmbH
Tibotec-Virco
Ventana Medical Systems
Visible Genetics
Vysis
Wyeth


Table of contents | Sample Pages ~Molecular Diagnostics (single user print version)|757|Molecular Diagnostics (Eletronic site license PDF + One print Copy)|758|~2484~2684~~
The World Market for In Vitro Diagnostics, 2005~
Published by Visiongain, January 2005

This year, the world market in 2005 for In Vitro Diagnostics will be in excess of $20bn - but what will it be next year, or in 2009? visiongain's brand new management report has the answers. The largest market is for Molecular Diagnostics, but will it continue to grow? The US currently dominates the market, whilst Germany has the largest market in Europe, but is also the third in the world.~
Published by Visiongain, January 2005

This year, the world market in 2005 for In Vitro Diagnostics will be in excess of $20bn - but what will it be next year, or in 2009? visiongain's brand new management report has the answers. The largest market is for Molecular Diagnostics, but will it continue to grow? The US currently dominates the market, whilst Germany has the largest market in Europe, but is also the third in the world.Visiongain's senior-level report tackles these topics, in-depth:

-- Regulation
-- Molecular Technologies
-- Nucleic Acid Testing
-- Protein Chip Technologies
-- In Vitro Diagnostics at Point of Care Use
-- Personal use of In Vitro Diagnostics
-- Future Use of In Vitro Diagnostics in Diabetes
-- Future Use of In Vitro Diagnostics in Cancer
-- In Vitro Diagnostics in Cardiac Monitoring
-- Genetic Testing
-- Future Markets
-- Future Growth Areas

PLUS MUCH MUCH more...

This in-depth 120+ page report contains over 30 tables, news, insights, the latest developments, and a complete survey of the World Market for In Vitro Diagnostics. This report is a vital addition in the understanding of this lucrative and fast growing market arena. You can not afford to do without this latest report from visiongain.

This report is packed with industry data, brought together from primary and secondary sources. With company analysis, country breakdowns, government findings, and visiongain analysis, this annual report is regarded as the leading in its field. The rapid growth of molecular diagnostics has increased as the proliferation of information concerning the human genome have paved the way for commercial diagnostic protocols based on developing technologies. You need to remain aware of changes and developments in this market and only one report can do this for you. visiongain's report is only available now and only by ordering it today can you stay fully informed and up-to-date. I look forward to receiving your order, today.

Table of Contents | Sample Pages~ The World Market for In Vitro Diagnostics, 2005 (Single user License PDF)|683| The World Market for In Vitro Diagnostics, 2005 (Department License PDF)|984| The World Market for In Vitro Diagnostics, 2005 (Company wide license PDF)|985|~2484~2487~~

Menu Page | Toolbar Page |
Frameset Page | Index Page | Table of Contents
EROL - Electronic Retail Online E-commerce shopping cart software